US Stock Insider Trading | Uron Pharmaceuticals Discloses 3 Insider Transactions on February 4

2026-02-19 01:34:20

On February 4, 2026, Ulong Pharmaceuticals (URGN) disclosed three insider trading transactions. Executive Schoenberg Mark sold 3,686 shares on February 3, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 4, 2026	Executive	Schoenberg Mark	February 3, 2026	Sell	3,686	19.69	$36,370
November 20, 2025	Executive	Schoenberg Mark	November 19, 2025	Sell	10,000	25.00	$250,000
October 9, 2025	Executive	Degnan Chris	October 8, 2025	Sell	2,203	16.85	$37,071
September 9, 2025	Executive	Smith Jason Drew	September 8, 2025	Sell	1,520	19.11	$29,011
September 9, 2025	Executive	Schoenberg Mark	September 8, 2025	Sell	871	19.11	$16,629
August 13, 2025	Executive	Schoenberg Mark	August 11, 2025	Sell	10,000	17.69	$176,900
July 30, 2025	Executive	Smith Jason Drew	July 28, 2025	Sell	7,522	19.14	$143,985
July 30, 2025	Executive	Schoenberg Mark	July 28, 2025	Sell	5,149	19.14	$98,471
June 11, 2025	Executive	Schoenberg Mark	June 9, 2025	Sell	5,162	7.37	$38,043
February 4, 2025	Executive	Schoenberg Mark	January 31, 2025	Sell	4,551	11.14	$50,693

[Company Information]

Ulong Pharmaceuticals Ltd. was incorporated in Israel in April 2004 under the name TheraCoat Ltd. In September 2015, the company changed its name to Ulong Pharmaceuticals Ltd. It is a clinical-stage biopharmaceutical company focused on developing novel therapies aimed at changing the standards of urological pathology care.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes